SCHEMBL23218749

SCHEMBL23218749

CCOC(=O)Cc1ccccc1OCc1coc2c(NCC3CCCO3)cc(-c3cccc(CN)c3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 6/20 0.43
F11 P03951 2/20 0.41
KLKB1 P03952 2/20 0.41
PLG P00747 1/20 0.41
PLAU P00749 1/20 0.41
F7 P08709 1/20 0.41
TPSB2 P20231 1/20 0.41
HPGD P15428 2/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
POLB P06746 1/20 0.34
CCR5 P51681 1/20 0.34
MEN1 O00255 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX12 P18054 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852936 1.00 CFD (0.43) CFDF11KLKB1PLGPLAU
SCHEMBL29852846 1.00 CFD (0.43) CFDF11KLKB1PLGPLAU
SCHEMBL23229051 0.95 HPGD (0.39) CFDHPGDALDH1A1KDM4EMAPT
SCHEMBL29852634 0.91 CFD (0.51) CFDF11KLKB1PLGPLAU
SCHEMBL23218935 0.91 CFD (0.51) CFDF11KLKB1PLGPLAU
SCHEMBL29853209 0.91 CFD (0.51) CFDF11KLKB1PLGPLAU
SCHEMBL23218081 0.91 CFD (0.51) CFDF11KLKB1PLGPLAU
SCHEMBL23218795 0.90 CFD (0.45) CFDF11KLKB1PLGPLAU
SCHEMBL29852994 0.90 CFD (0.45) CFDF11KLKB1PLGPLAU
SCHEMBL23218705 0.90 CFD (0.46) CFDF11KLKB1PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885KLKB1 370/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885KLKB1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.